In March 2021, Relief entered into a collaboration and license agreement with Acer Therapeutics for the worldwide development and commercialization of late-stage development candidate, ACER-001.
In January 2021, Relief signed a binding term sheet to acquire all shares of AdVita. Amongst the AdVita assets being acquired in this transaction, Relief will gain further pending intellectual property rights that may cover RLF-100™ inhaled formulation.
In May 2021, Relief signed a binding term sheet to acquire all outstanding shares of APR Applied Pharma Research. APR already has products on the market in addition to a clinical portfolio in rare or debilitating diseases with high unmet medical need that is synergistic with Relief’s current development pipeline.
Topline data announced in U.S. Phase 2b/3 trial with RLF-100™
In March 2021, Relief’s partner NeuroRx reported top-line 60-day results from the U.S. IV Phase 2b/3 clinical trial evaluating RLF-100™ IV in critical COVID-19 patients with respiratory failure.